278 related articles for article (PubMed ID: 30101616)
21. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
Takahashi A; Suzuki T
Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
[TBL] [Abstract][Full Text] [Related]
22. A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs.
Chiuzan C; Garrett-Mayer E; Yeatts SD
Clin Trials; 2015 Feb; 12(1):24-33. PubMed ID: 25349178
[TBL] [Abstract][Full Text] [Related]
23. Isotonic designs for phase I trials.
Leung DH; Wang Y
Control Clin Trials; 2001 Apr; 22(2):126-38. PubMed ID: 11306151
[TBL] [Abstract][Full Text] [Related]
24. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Zang Y; Lee JJ
Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
[TBL] [Abstract][Full Text] [Related]
25. A design for phase I trials in completely or partially ordered groups.
Conaway MR
Stat Med; 2017 Jul; 36(15):2323-2332. PubMed ID: 28384843
[TBL] [Abstract][Full Text] [Related]
26. Data-dependent early completion of dose-finding trials for drug-combination.
Kojima M
Stat Methods Med Res; 2023 Apr; 32(4):820-828. PubMed ID: 36775992
[TBL] [Abstract][Full Text] [Related]
27. A web tool for designing and conducting phase I trials using the continual reassessment method.
Wages NA; Petroni GR
BMC Cancer; 2018 Feb; 18(1):133. PubMed ID: 29402249
[TBL] [Abstract][Full Text] [Related]
28. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
[TBL] [Abstract][Full Text] [Related]
29. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose.
Qiu Y; Zhao Y; Liu H; Cao S; Zhang C; Zang Y
Contemp Clin Trials; 2023 Apr; 127():107139. PubMed ID: 36870476
[TBL] [Abstract][Full Text] [Related]
30. Isotonic designs for phase I cancer clinical trials with multiple risk groups.
Yuan Z; Chappell R
Clin Trials; 2004; 1(6):499-508. PubMed ID: 16279290
[TBL] [Abstract][Full Text] [Related]
31. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
32. Fractional dose-finding methods with late-onset toxicity in phase I clinical trials.
Yin G; Zheng S; Xu J
J Biopharm Stat; 2013; 23(4):856-70. PubMed ID: 23786314
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial design for drug combinations with Bayesian model averaging.
Jin IH; Huo L; Yin G; Yuan Y
Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
[TBL] [Abstract][Full Text] [Related]
34. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
35. A robust Bayesian dose-finding design for phase I/II clinical trials.
Liu S; Johnson VE
Biostatistics; 2016 Apr; 17(2):249-63. PubMed ID: 26486139
[TBL] [Abstract][Full Text] [Related]
36. Bayesian optimal interval design for dose finding in drug-combination trials.
Lin R; Yin G
Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
[TBL] [Abstract][Full Text] [Related]
37. A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.
Kakurai Y; Hirakawa A; Hamada C
J Biopharm Stat; 2015; 25(5):1065-76. PubMed ID: 25369852
[TBL] [Abstract][Full Text] [Related]
38. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
Muenz DG; Braun TM; Taylor JM
Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
[TBL] [Abstract][Full Text] [Related]
39. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
Ivanova A; Wang K
Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
[TBL] [Abstract][Full Text] [Related]
40. Accelerated titration designs for phase I clinical trials in oncology.
Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
